Literature DB >> 9544166

Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major.

M Aker1, J Kapelushnik, T Pugatsch, E Naparstek, S Ben-Neria, O Yehuda, A Amar, A Nagler, S Slavin, R Or.   

Abstract

PURPOSE: Donor lymphocyte infusion (DLI) was used to reverse relapse after allogeneic bone marrow transplantation (BMT) in a patient with beta-thalassemia major. PATIENTS AND METHODS: The patient with unstable mixed chimerism after BMT was treated with graded increments of donor lymphocytes (10(5) T cells/kg to 5 x 10(7) T cells/kg) to displace residual hematopoietic host cells.
RESULTS: DLI resulted in complete donor-derived reconstitution of the hematopoietic compartment. The patient developed mild graft-versus-host disease (GVHD) that could be controlled by steroid treatment.
CONCLUSIONS: This case report shows that DLI can effectively eradicate host stem cells in mixed chimeras after BMT in nonmalignant hematopoietic diseases.

Entities:  

Mesh:

Year:  1998        PMID: 9544166     DOI: 10.1097/00043426-199803000-00011

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

Review 1.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 2.  Stem cell transplantation for thalassemia.

Authors:  Surapol Issaragrisil
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 3.  Graft-versus-host disease, the graft-versus-leukemia effect, and mixed chimerism following nonmyeloablative stem cell transplantation.

Authors:  Shimon Slavin
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

4.  An Experience of Donor Lymphocyte Infusion after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease.

Authors:  Tahereh Rostami; Azadeh Kiumarsi
Journal:  Pediatr Rep       Date:  2020-12-11

5.  Unmanipulated Stem Cell Boost for Mixed Chimerism in Transfusion Dependent Thalassemia.

Authors:  Akanksha Garg; Akshay Shivchhand; Sandip Shah; Kamlesh Shah; Kinnari Patel; Harsha Panchal; Apurva Patel; Sonia Parikh
Journal:  Indian J Hematol Blood Transfus       Date:  2020-09-03       Impact factor: 0.915

6.  Long--Term Free Survival of Two Class III β-Thalassemic Patients after Non-Myeloablative Stem Cell Transplantation.

Authors:  Mohammad Mahdi Adib Sereshki; Babak Bahar; Ardeshir Ghavamzadeh; Seyed Asadollah Mousavi; Kamran Alimoghaddam
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.